Regeneron Pharmaceuticals said it will take a $22 million pretax charge for an acquired in-process research-and-development charge that will reduce its third-quarter reported and adjusted earnings by about 18 cents a share. Analysts expect adjusted EPS of $16.00.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
